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Summary Electrochemotherapy (ECT) enhances the effectiveness of chemotherapeutic agents by administering the drug in combination
with short intense electric pulses. ECT is effective because electric pulses permeabilize tumour cell membranes and allow non-permeant
drugs, such as bleomycin, to enter the cells. The aim of this study was to demonstrate the anti-tumour effectiveness of ECT with bleomycin
on cutaneous and subcutaneous tumours. This article summarizes results obtained in independent clinical trials performed by five cancer
centres. A total of 291 cutaneous or subcutaneous tumours of basal cell carcinoma (32), malignant melanoma (142), adenocarcinoma (30)
and head and neck squamous cell carcinoma (87) were treated in 50 patients. Short and intense electric pulses were applied to tumours
percutaneously after intravenous or intratumour administration of bleomycin. The tumours were measured and the response to the treatment
evaluated 30 days after the treatment. Objective responses were obtained in 233 (85.3%) of the 273 evaluable tumours that were treated with
ECT. Clinical complete responses were achieved in 154 (56.4%) tumours, and partial responses were observed in 79 (28.9%) tumours. The
application of electric pulses to the patients was safe and well tolerated. An instantaneous contraction of the underlying muscles was noticed.
Minimal adverse side-effects were observed. ECT was shown to be an effective local treatment. ECT was effective regardless of the
histological type of the tumour. Therefore, ECT offers an approach to the treatment of cutaneous and subcutaneous tumours in patients with
minimal adverse side-effects and with a high response rate.
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Chemotherapy is a widely used treatment for a broad range of
cancers. In many instances, the response rate is low. In melanoma,
for example, partial response rates range from 20% to 45%, with
complete responses of less than 5% (Buzaid and Murren, 1992;
Coates, 1992; Nathanson and Jilani, 1993; Yeung, 1994). One
possible reason for this low response rate is the difficulty of some
drugs to cross the cell membrane and reach their intracellular site
of action. The application of short and intense electric pulses can
reversibly permeabilize membranes of all living cells, including
mammalian, bacterial, yeast and plant cells (Mir et al, 1988;
Neumann et al, 1989; Rols and Teissie, 1990; Orlowski and Mir,
1993). These electric pulses have been used in vitro to introduce
drugs, foreign DNA and other exogenous molecules into cells
(Orlowski and Mir, 1993).
Bleomycin is a very potent cytotoxic molecule when introduced
inside the cell. A few hundred molecules are sufficient to be cyto-
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toxic (Poddevin et al, 1991; Tounekti et al, 1993). However,
bleomycin does not freely diffuse through the plasma membrane
and has very limited access to the cytosol (Orlowski et al, 1988;
Poddevin et al, 1991). Bleomycin normally enters cells through
interaction with a membrane protein that mediates its internaliza-
tion (Pron et al, 1993). Response is a function of the presence or
absence of this membrane protein (Pron et al, 1993; 1994). This
could be a significant reason why bleomycin has had limited
success as an anti-tumour agent. Electropermeabilization of cells
as well as tissues allows bleomycin to enter the cytosol directly
and to exert fully its cytotoxic potential (Orlowski et al, 1988;
Poddevin et al, 1991; Tounekti et al, 1993; Belehradek et al, 1994).
Therefore, bleomycin is an excellent candidate for combining with
electric pulses because it is non-permeant and at the same time
highly cytotoxic once inside the cell.
The anti-tumour effectiveness of bleomycin was shown to be
greatly increased by the local delivery of permeabilizing electric
pulses at the tumour in preclinical trials with mice (Belehradek et al,
1991; Mir et al, 1991). The permeabilizing effect is restricted to an
area encompassed by the electrodes. Electric pulses delivered after
the administration of bleomycin actually increased drug delivery to
tumours (Belehradek et al, 1994). However, electric pulses delivered
alone did not elicit an anti-tumour response. Anti-tumour effects
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were observed in many different animal models (Mir et al, 1991;
Belehradek et al, 1991; Salford et al, 1993; Mir, 1994; Ser'sa et al,
1994; 1995; Yamaguchi et al, 1994; Cemazaret al, 1995; Helleret al,
1995). Anti-tumour treatment with this combined therapy can be
used in tumour systems in which bleomycin alone was not typically
used (Mir et al, 1996). This new anti-tumour therapy that combines
the administration of a non-permeant drug such as bleomycin with
local permeabilizing electric pulses was termed electrochemotherapy
(ECT) (Mir et al, 1991; Mir, 1994). The principle of ECT is charac-
terized by a more efficient manner ofdrug delivery that increases the
effectiveness ofthe administered drug with reduced side-effects.
The first ECT clinical trial performed in Villejuif, France,
treated cutaneous nodules of metastatic squamous cell carcinoma
present on the head and neck (Belehradek et al, 1993). Objective
responses were obtained in 72% of 40 treated nodules in eight
patients. The therapy was well tolerated by the patients. Pre-
liminary sedation 1 h before ECT or in one case short neurolept-
analgesia was used. Subsequently, several clinical trials have been
initiated in other cancer centres. Preliminary reports ofthese trials
on 15 patients have been published (Heller, 1995; 1996; Rudolf et
al, 1995; Domenge et al, 1996). Patients with basal cell carcinoma,
malignant melanoma, adenocarcinoma or squamous cell carci-
noma were enrolled in these trials to determine if ECT is applic-
able to tumours of other histological types. All trials used
bleomycin, which was administered several minutes before
delivery of electric pulses. This report presents a summary of
results obtained from clinical trials performed independently in
five cancer centres and included the treatment of 291 tumours in
50 patients.
PATIENTS AND METHODS
Patients and inclusion criteria
Ten patients with basal cell carcinoma (BCC), 20 with metastatic
malignant melanoma, three with adenocarcinoma of the salivary
gland or breast and 17 with head and neck squamous cell carci-
noma (HNSCC) were entered in trials initiated in five different
cancer centres. These were located in Villejuif (VI), Toulouse
(TO), Reims (RE), France; Ljubljana (LJ), Slovenia; and Tampa
(TA), United States. A total of 32 primary BCC tumours, 142
metastatic malignant melanoma deposits, 30 adenocarcinoma
subcutaneous metastases and 87 metastatic HNSCC nodules were
treated in 66 sessions. At the time of their inclusion in ECT trials,
patients with primary BCC of the skin had previous surgery or
multiple lesions and refused additional conventional therapies,
such as surgery. Patients with metastatic malignant melanoma,
adenocarcinoma and HNSCC presented with recurrent lesions
after several previous treatments by surgery, radiotherapy and/or
chemotherapy. Of the total patient population, only 2 of the 50
(both malignant melanoma) had received bleomycin before ECT.
Signed informed consent was obtained from all patients. Trials
were performed after approval of the corresponding ethics and
institutional review committees.
Protocols for bleomycin administration
Bleomycin was injected intravenously (i.v.), in a rapid bolus (30 s
duration) at least 3 min before electric pulse delivery (VI, TO, RE
and LJ). The bleomycin dose was either 18 units m-2 (10 mg m-2) or
27 units m-2 (15 mg mr2). Alternatively, bleomycin was injected
either i.v., 10 units m-2 (5.6mg m-2) at an infusion rate of 1.5 units
min-', or intratumorally (i.t.), 0.25 to 1.0 units per treated tumour in
less than 30 s at least 10 min before electric pulse delivery (TA).
Protocols for electric pulse delivery
Treatment included applying rectangular-wave electric pulses
directly to tumours after bleomycin administration. The French and
Slovenian centres (VI, RE, TO and LJ) used electrodes that
consisted of two stainless steel strips 10mm wide and 0.6 mm
thick. Insulating material was used to maintain a fixed gap between
the two strips. Spacing between the electrodes was 7 mm for VI,
RE and LJ and 6 mm forTO. Electric pulses were delivered by a PS
15 electropulsator (Jouan, Nantes, France) that was designed to
obey the electric current limits set by the European Community
(Commissionfor Industrial Electricity, 1984). The US centre (TA)
used electrodes consisting of two stainless steel squares of 20 mm
mounted on a vernier caliper or a circular array of six needles. The
caliper-mounted electrodes allowed the gap to be adjusted
according to the size of the tumour and the needle array electrode
was fixed at a 10 mm diameter. Electric pulses were delivered by a
BTX T820 generator (Genetronics, San Diego, CA, USA).
Table 1 Patient information and response to treatment
Histological type Mean Mean Response to
patient age tumour diameter electrochemotherapy
(range) (mm) (range)
Basal cell carcinoma 55.8 7.7 1O00% OR
10 patients, 32 tumours (38-71) (4-14) (75% CR, 25% PR)
Melanoma 55.5 8.1 92.2% OR
20 patients, 142 tumours (33-76) (2-52) (52.8% CR, 39.4% PR)
Adenocarcinoma 54.3 8.5 100% ORa
3 patients, 30 tumours (39-67) (3-17) (100% CR)
Squamous cell carcinoma 53.0 17.5 62.3% ORb
17 patients, 87 tumours (37-67) (3-125) (42.8% CR, 19.5% PR)
Total 54.6 11.24 85.3% ORC
50 patients, 291 tumours (37-76) (2-125) (56.4% CR, 28.9% PR)
OR, objective responses; CR, complete responses; PR, partial responses. aBased on 22 evaluable tumours; bbased on 77 evaluable tumours;
cbased on 273 evaluable tumours.
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Table 2 Responses of basal cell carcinoma tumours treated with electrochemotherapy
Patient Bleomycin Electric Number of Response
dose (units)a pulsesb tumours
TA4 i.v./10 8 4 1 CR, 3 PR
TA5 i.v./10 8 2 2 PR
TA7 i.t./2.25 8 3 3 CR
TA8C i.t.l2.75/5.5/4 8/6/6 3/2/5 7 CR, 3 PR
TA9 i.t./1.75 8 2 2 CR
TAll i.t./4 8 4 4 CR
TA13 i.t./O.5 8 1 1 CR
TA16 i.t./2.0 6 2 2 CR
TA17 i.t./2.0 6 2 2 CR
TA19 i.t./1.25 6 2 2 CR
aBleomycin dose and route of administration; i.v., intravenous; i.t., intratumour. bElectric pulses - number of electric pulses
administered to each treated tumour. cPatient treated in three sessions.
Table 3 Responses of melanoma tumours treated with electrochemotherapy
Patient Bleomycin Electric Number of Response
dose (units)a pulsesb tumours
TAl iv.10 8 4 3SDC, 1 PDC
TA2 i.v./10 8 4 3CR, 1 SD
TA3 i.v./10 8 2 2 PR
TAJOd i.t./l.5/3.0 8/6 2/2 3CR, 1 PR
TA12d i.t./5.0/6.0 8/6 6/5 11 CR
TA14d i.t./5.25/6.5 6/6 5/17 22 CR
TA15 i.t./5.75 6 4 3 PR, 1 PD
TA18 i.t./5.5 6 3 3 CR
TA20 i.t./2.75 6 4 4 CR
LJ1d i.v./18/18 4+4/4+4 3/3e 3 CR
LJ2 i.v./18 4+4 1 1 PR
LJ3 i.v./18 4+4 1 1 SDf
LJ4 i.v./18 4+4 2 2 CR
LJ5 i.v./18 4+4 1 1 PRf
LJ6g i.v./18/18/18 4+4/4+4/4+4 2/6/13 19CR, 1 SD, 1 PDc
LJ7 i.v./18 8 1 1 PR
TO2d i.v./18/18 4/4 10/1be 10 PR
T03 i.v./18 4 22 4 CR, 18 PR
T04 i.v./18 8 11 10 PR, 1 SD
TO5 i.v./18 8 11 1 CR, 9 PR, 1 SD'
aBleomycin dose and route of administration; i.v., intravenous; i.t., intratumour. bElectric pulses - number of electric pulses administered to each treated tumour.
cTumours located in areas poorly perfused by blood as indicated in text. dPatient treated in two sessions. eSame tumours treated in two sessions. fNot the whole
tumour area was treated. gPatient treated in three sessions.
Table 4 Responses of adenocarcinoma tumours treated with electrochemotherapy
Patient Origin Bleomycin Electric Number of Response
dose (units)a pulsesb tumours
TA6 Breast i.v./10 8 2 2 CR
V19 Salivary gland i.v./27 4 20 20 CR
V115 Breast i.v./27c 4 8 8 NEd
aBleomycin dose and route of administration; i.v., intravenous; i.t., intratumour. bElectric pulses - number of electric pulses administered to each treated tumour.
cOwing to the time required to treat the large tumours, a supplement of bleomycin was administered. dTumours were non-evaluable because of too short follow-up.
Either four, six or eight electric pulses were delivered per treat-
ment site by placing electrodes on the skin adjacent to the tumour.
Electric pulses were delivered at a rate ofonepulse per second. All
the patients treated in VI, TO, RE and LJ received either four or
eight electric pulses. In LJ this was accomplished by delivering
four pulses then rotating the electrodes 900 and administering four
additional pulses. This is denoted as a4+4 configuration (Cemazar
et al, 1995). Patients treated in TA received either eight (caliper
electrodes) or six (needle array electrode) electric pulses. The ratio
of voltage to electrode distance was 1300 V cm-' for all teams,
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except when otherwise stated. Skin contact was ensured by means
of electrocardiography paste and shaving when necessary. For the
treatment of small tumours, electrodes were placed at each side of
the tumour and one series ofelectric pulses was delivered. For the
treatment of large tumours, sequential electrical treatments were
delivered at adjacent positions in order to cover the entire tumour
surface.
Before administration ofelectric pulses, patients received either
local or systemic anaesthesia. patients at VI with a small number
of treatment sites received only sedatives (lorazepan or levome-
promazine). Patients at VI, RE or TO with large tumours or with
numerous sites were treated under neuroleptanalgesia using mida-
zolam and alfentanil or under general anaesthesia. Patients at LJ
received lidocaine spray over the treated surface. Patients at TA
received a peritumoural injection of 1-3 ml of 1% lidocaine per
lesion.
Follow-up
During ECT and some hours later, patients were carefully moni-
tored for treatment side-effects. The first few patients in the trial
(VI 1-7) and any patient treated under neuroleptanalgesia or
complete anaesthesia (VI 8-15, TO and RE) remained in the
hospital for 24 h. In the other cases, the procedure was performed
on an outpatient basis. All ofthem were examined as outpatients at
regular intervals after ECT. Tumour measurements were made
using a vernier caliper, and documented with photographs.
Response rates were based on the tumour volume by measuring
the longest diameter (a) and the next longest diameter (b) perpen-
dicular to a. The tumour volume (V) was calculated by the
formula: V = tab2/6.
When the results were analysed on a per treated nodule basis,
the number ofobjective responses (OR) was determined by adding
the number ofcomplete responses (CR, no palpable or measurable
tumour detected for at least 30 days after treatment) and partial
responses (PR, greater than 50% decrease in tumour volume for at
least 30 days after treatment). Stable disease (SD) was defined as
no growth but less than 50% reduction in tumour volume; and
progressive disease (PD) was defined as continued growth. To
determine the response rate perpatient, thepoorestresponse on the
per treated nodule basis was taken into account.
RESULTS
Clinical response
A total of 50 patients were treated at five different cancer centres
in 66 ECT sessions. This included a total of 291 tumours of
various sizes and of various histological types (Table 1). Of the
291 sites treated, 273 were evaluable. Objective responses were
found in 233 (85.3%) of the evaluable tumours of which 154
(56.4%) were CR and 79 (28.9%) were PR. On a perpatientbasis,
48 patients were evaluable. Objective responses were found in 31
(64%) of the evaluable patients of which 17 (35%) were CRs and
14 (29%) were PRs.
Basal cell carcinoma
Among the 32 BCC primary tumours treated (ten patients), a 100%
response rate was observed after ECT(Table 2). Ofthese, 24 (75%)
disappeared within 1 month and did not recurduring a mean follow-
up of 15 months (range 6-27 months) and were designated CRs.
The othereight (25%) were found to be PRs. On a perpatientbasis,
we obtained seven CRs (70%) and three PRs (30%). The size ofall
15 control BCCs treated with either bleomycin or electric pulses
aloneprogressedduring theperiod ofobservation (100% PD).
The first two BCC patients were treated with an i.v. dose of
bleomycin. Only one of the six (16.7%) tumours treated in these
patients was a CR and five were PRs. The number of CRs after
i.v. administration of bleomycin was unacceptable for BCC.
Therefore, the othereight BCC patients receivedbleomycin i.t. In
these patients CRs were found in 23 of 26 tumours and three were
Table 5 Responses of head and neck squamous cell carcinoma tumours treated with electrochemotherapy
Patient Bleomycin Electric Number of Response
dose (units)a pulseSb tumours
VIlc i.v./18/18 4/4 1/11 12 CR
V12 i.v./18 4 1 1 SD
V13 i.v./18 4 6 6 SD
V14 i.v./18 4 1 1 PR
Vl5 i.v./18 4 1 1 SD
V16c i.v./ 8/18 8/8 3/8 3 CR, 5 PR, 3 SD
V17 i.v./18 8 2 2 CR
Vl8d i.v./ 8/27/18 8/4e/4e 1/3/4 6 CR, 1 SD, 1 PD'
Vllod i.v.127/27/27 4/4/4 5/1/2 1 CR, 3 PR, 3 SD, 1 PD
Vili i.v./27 8 6 3 CR, 1 PR, 2 SD
V112 i.v./27 4e 10 10 NEs
V113 i.v./27 4 3 1 PR, 2 SD
V114c i.v./27/27h 4/4 2/2i 2 PD
RE1 i.v./27 4 2 1 CR, 1 PR
RE2 i.v./27 4 2 2 PR
RE3 i.v./27 4 6 2 SD, 4 PD
T01 i.v./18 4 6 5CR, 1 PR
aBleomycin dose and route of administration; i.v., intravenous; i.t., intratumour. bElectric pulses - number of electric pulses administered to each treated tumour.
cPatient treated in two sessions. dPatient treated in three sessions eFour electric pulses at a field strength of 1000 V cm-' were administered. 'Tumour pulsed
outside the therapeutical window after bleomycin injection. gTumours were non-evaluable because of too short follow-up. hBleomycin was administered intra-
arterially. iSame tumours treated in two sessions.
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PRs. Two of the PRs were retreated and CRs were obtained.
Therefore, examining BCCs that received an i.t. dose ofbleomycin
and one or two treatments, CRs were obtained in 25 of26 (96.2%)
treated tumours.
Melanoma
Objective responses were seen in 131 (92.2%) of the 142
metastatic malignant melanoma nodules (20 patients) treated
(Table 3). CRs were seen in 75 (52.8%) ofthe treated tumours that
rapidly disappeared within 1-2 weeks after ECT. No regrowth of
these nodules was reported. PRs were seen in 56 (39.4%) of the
treated sites. On a per patient basis, we obtained six CRs (30%)
and seven PRs (35%). All 15 control nodules treated with
bleomycin alone were observed to have PD.
Of the 11 (7.7%) metastatic melanoma nodules that did not
respond to ECT, two nodules were situated in a way that the entire
tumour could not be treated. A total of five other treated tumours
in two patients were located in poorly perfused areas. These two
patients received i.v. bleomycin, which could account for the lack
of response.
Adenocarcinoma
All 22 (100%) evaluable adenocarcinoma metastatic nodules
(three patients) responded to ECT (Table 4). All of these were
found to be CRs. Eight additional metastatic nodules were treated
but could not be evaluated because of a too short follow-up period.
The two control nodules receiving bleomycin alone had PD.
Head and neck squamous cell carcinoma
Objective responses were seen in 48 (62.3%) of the 77 HNSCC
evaluable nodules (17 patients) treated (Table 5). Ofthese nodules,
33 (42.8%) were in CR and 15 (19.5%) in PR. Only eight (10.3%)
of the nodules were PDs. Ten additional nodules were not evalu-
ated because of too short follow-up ofthe patient. On a per patient
basis, we obtained two CRs (12%) and four PRs (24%). In the case
of the HNSCC nodules, it was necessary to distinguish between
nodules that could be encompassed with one treatmentusing trans-
cutaneous electric pulses and the very large nodules treated with
sequential electrical treatments. The treatment ofthe large nodules
was important for the determination of some parameters and
constraints of electrochemotherapy. For these large nodules,
massive necrosis and reduction in the height of the nodule was
observed but, as expected, the deepest parts were not completely
affected by ECT, presumably because they were not crossed by an
electric field of sufficient intensity.
Tolerance during and after the treatment
No significant modification of haemodynamic or cardiological
parameters was noticed during ECT. A contraction of muscles
located beneath the site of treatment was observed. The contrac-
tions were instantaneous, disappearing immediately after the end
of each electric pulse (1/10 000th of a second in length). Several
procedures, either local or systemic, as described above, were used
for relief of the sensations that accompanied the contractions.
General anaesthesia seems more appropriate when large and/or
multiple nodules are treated, whereas local anaesthesia would be
sufficient for the treatment of a few small tumours.
Erythema and slight oedema at the site ofthe treated areas were
the only noticeable symptoms observed transiently and remained
less than 24 h. Transient marks from electrodes were also often
visible after ECT. Superficial leuconecrosis was observed in the
case of the large tumours for which the skin was already altered
before ECT. For patients receiving only sedatives or local anaes-
thesia, some pain was involved during the procedure, which
subsided immediately after the last pulse was delivered. All
patients agreed that it was tolerable and they would undergo the
procedure again. As a matter of fact, several patients returned for
treatment of additional lesions. In addition, no delayed pain was
reported by the patients. In several cases, the pain associated with
the tumour was attenuated after ECT. No enhanced systemic
bleomycin toxicity was observed.
DISCUSSION
Results reported here from five cancer centres included the treat-
ment of 273 evaluable tumours with an objective response rate of
85.3%. ECT was safe and well tolerated by the patients. The high
rate ofobjective responses was obtained regardless ofthe histolog-
ical type of the treated tumours. These results are encouraging for
the future development of ECT and illustrate that ECT has the
potential to be a potent anti-tumour treatment even when the treat-
ment protocol is varied.
The high rate of objective responses obtained regardless of
histological type is in agreement with the fundamental basis of
ECT. Cell electropermeabilization is a universal phenomenon
occurring in all types of living cells and results from the interac-
tion of electric fields with a low conductive membrane composed
of lipids and proteins (Neumann et al, 1989; Orlowski and Mir,
1993). Once inside the cell, interaction of bleomycin with DNA
results in a chemical reaction that generates highly cytotoxic DNA
double-strand breaks (Poddevin et al, 1991; Tounekti et al, 1993).
Thus, all histological types oftumours should be sensitive to ECT.
Electric pulses have to be delivered during the period for which
the interstitial bleomycin concentration in the tumour is sufficient.
This period was determined in one of the clinical situations exam-
ined (HNSCC) to be from 8 to 28 min after bleomycin i.v. bolus
injection. This time frame is perhaps longer if bleomycin is
injected slowly (for example at a rate of 1.5 units min-'). However,
the concentration of bleomycin at the treatment site is probably
lower. Although there is a defined window of opportunity for
successful treatment when administering bleomycin i.v., this does
not present a problem because the procedure for applying electric
pulses is very rapid (4-8 s) and can be repeated many times inside
the therapeutical window in the case of very large tumours or
several tumours.
An alternative procedure to i.v. bleomycin administration is i.t.
injection, which proved to be effective as well. Moreover, if
tumour treatment is associated with a local approach for analgesia,
then every tumour can be treated independently, and the whole
ECT session can be split in as many partial sessions as required.
The results found in these studies indicate that ECT is an effective
treatment irrespective of the bleomycin administration route.
Therefore, the treatment can be administered in a variety of ways
depending on the clinical situation.
An important observation was that ECT was safe and resulted in
minimal side-effects. In particular, no significant modification of
the haemodynamic or cardiological parameters was noticed even
when the treated tumours were located in the chest above the
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cardiac region. However, there is a contraction of the muscles
located beneath the electrodes as the muscle cells are excited by
the electric pulses. Many patients had disagreeable sensations
associated with the delivery ofelectric pulses. This was short lived
and disappeared immediately after pulsing. In addition, sometimes
transient marks from the electrodes were visible.
Thus, at the present time, ECT can already be considered as an
effective treatment, whatever the histological type of the tumour.
ECT has been efficient on multiple BCCs in patients previously
disfigured by surgery who refused further surgery. Scarring was
minimal in the treated sites, which makes ECT an obvious advan-
tage over a surgical excision. ECT was also effective as a local
treatment for malignant melanoma with a 92.2% objective
response. ECT has also proven anti-tumour effectiveness on other-
wise untreatable HNSCC nodules as these nodules, resistant to
conventional chemotherapy, were located in areas previously
treated by surgery and radiotherapy. An important observation was
that results were consistent among the different centres even
though the procedure was varied. This highlights that the basic
premise of ECT, permeabilization of tumour cells in the presence
of a chemotherapeutic agent, is the key to successful therapy.
Thus, the most appropriate chemotherapeutic agent for this kind of
treatment is not the usual appropriate drug for each specific situa-
tion but a non-permeant drug (such as bleomycin) for which the
cytotoxicity will be highly potentiated by tumour cell electroper-
meabilization, whatever the carcinological situation.
ECT has been demonstrated to be an effective local treatment
that can be added to the usual set of local anti-cancer therapies. For
the treatment of metastatic diseases it is important to add a
systemic component to ECT. Therefore, in preclinical trials, ECT
has been combined with immunotherapy. Systemic effect demon-
strated by responses ofdistant tumours was obtained by combining
local ECT with the local administration ofhistoincompatible inter-
leukin 2 (IL-2)-secreting cells in a murine model (Mir et al, 1995).
In addition, local anti-tumour effect was enhanced by the local
administration of IL-2 (Mir et al, 1992). Thus, the combination of
ECT with immunotherapy may lead to a wider applicability of the
technique by producing a systemic anti-tumour treatment.
New possibilities of ECT are presently being explored in
preclinical trials with the use of cisplatin. Although cisplatin is a
more permeant drug than bleomycin its effectiveness was also
augmented by electropermeabilization of cells in vitro as well as
tumours in vivo (Sersa et al, 1995). Cisplatin is currently used in
many chemotherapeutic protocols. Therefore, ECT with cisplatin
can be useful in patients as an adjuvant to ongoing cisplatin treat-
ment. These results are encouraging and suggest that the effective-
ness of other anti-tumour agents may also be augmented by
electropermeabilization.
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